Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART
- 14 May 2009
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 65 (7) , 667-678
- https://doi.org/10.1007/s00228-009-0660-5
Abstract
To assess the relationship between genetic polymorphisms and indinavir pharmacokinetic variability and to study the link between concentrations and short-term response or metabolic safety.Keywords
This publication has 48 references indexed in Scilit:
- Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen - ANRS 111 trialFundamental & Clinical Pharmacology, 2009
- Comparison of Model-Based Tests and Selection Strategies to Detect Genetic Polymorphisms Influencing Pharmacokinetic ParametersJournal of Biopharmaceutical Statistics, 2008
- Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patientsBritish Journal of Clinical Pharmacology, 2008
- Validation of the CNS Penetration-Effectiveness Rank for Quantifying Antiretroviral Penetration Into the Central Nervous SystemArchives of Neurology, 2008
- Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV‐infected patientsBritish Journal of Clinical Pharmacology, 2007
- Estimation of Population Pharmacokinetic Parameters of Saquinavir in HIV Patients with the MONOLIX SoftwareJournal of Pharmacokinetics and Pharmacodynamics, 2007
- Clinical Pharmacokinetics of DarunavirClinical Pharmacokinetics, 2007
- Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivoClinical Pharmacology & Therapeutics, 2005
- High Variability of Indinavir and Nelfinavir Pharmacokinetics in HIV-Infected Patients with a Sustained Virological Response on Highly Active Antiretroviral TherapyClinical Pharmacokinetics, 2005
- RitonavirClinical Pharmacokinetics, 1998